Pharmacology of bisphosphonates

Cremers, Serge; Papapoulos, Socrates E.

doi:10.1016/j.bone.2011.01.014

Cited by 189 publications

(174 citation statements)

References 58 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…Nitrogen containing bisphosphonates (risedronate, zoledronate, pamidronate, alendronate) have a greater absorption affinity to bone than do non nitrogen containing bisphosphonates (etidronate, clodronate) [55,56]. A one-year study comparing pamidronate to zoledronate intravenous treatments in young OI patients showed a significantly greater increase in LS-aBMD with the later treatment (42.7 % versus 34.7 %, p=0.013) [57].…”

Section: Bisphosphonatesmentioning

confidence: 99%

Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial

Plante

Veilleux

Glorieux

et al. 2016

Bone

View full text Add to dashboard Cite

Background Osteogenesis imperfecta (OI) is a genetic disease characterized by fragile bones and short stature. Recently, a positive association was found between serum 25‐hydroxyvitamin D (25OHD) concentrations and lumbar spine areal bone mineral density (LS‐aBMD) z‐scores in this population. Objectives: To assess whether high‐dose vitamin D supplementation (2000 IU) will result in significantly higher LS‐aBMD z‐scores after one‐year; and to evaluate the effect of vitamin D supplementation on lower limb muscle power. Results: At baseline, average serum 25OHD concentration was 65.6 nmol/L (SD 20.4) with no difference seen between treatment groups (p=0.77). Deficient serum 25OHD concentrations (<50 nmol/L) were measured in only 21% of patients at baseline. Supplementation resulted in higher serum 25OHD concentrations in almost all participants (90%) with significantly higher increases seen with 2000 IU (mean [95% C.I.] = 30.5 nmol/L [21.3; 39.6] vs 15.2 nmol/L [6.4; 24.1], p= 0.02). No significant changes were detected in BMD measurements or in lower limb muscle power between treatment groups from baseline to final visit. Conclusions Supplementation with either 400 or 2000 IU of vitamin D translates into significant increases in serum 25OHD concentrations in children with OI. However, increases in baseline serum 25OHD concentrations already within a healthy range (蠅50 nmol/L) do not translate into increases in BMD z‐scores in children with OI. This research was supported by the Shriners Hospital for Children as well as by The Network for Oral and Bone Health Research.

show abstract

Section: Bisphosphonatesmentioning

confidence: 99%

Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial

Plante

Veilleux

Glorieux

et al. 2016

Bone

View full text Add to dashboard Cite

show abstract

“…Preclinical evidence suggests that dDTCs in distant organs can recolonize their tumors of origin. 24 This process called 'tumor self-seeding' could explain, for instance, the local recurrences in breast cancer. 24 In the ABCSG-12 study, patients receiving zoledronate experienced fewer locoregional recurrences compared with patients who received hormonal therapy alone (15 vs 29 at 62 months' follow-up).…”

Section: Clinical Evidence Supporting Antitumor Activity Of Bisphosphmentioning

confidence: 99%

“…24 This process called 'tumor self-seeding' could explain, for instance, the local recurrences in breast cancer. 24 In the ABCSG-12 study, patients receiving zoledronate experienced fewer locoregional recurrences compared with patients who received hormonal therapy alone (15 vs 29 at 62 months' follow-up). 17 Similarly, in the ZO-FAST trial, fewer recurrences were reported in the immediate-zoledronate group compared with the delayed-zoledronate group (5 vs 12 at 60 months' follow-up).…”

Section: Clinical Evidence Supporting Antitumor Activity Of Bisphosphmentioning

confidence: 99%

Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities

Clézardin

2013

BoneKEy Reports

View full text Add to dashboard Cite

“…When in the bloodstream, BPs are rapidly taken up by the bone tissue where they can prevent the resorption of bone. 1 This rare ability to bind specifically to bone forms the basis of their clinical use. BPs have several medical applications: treatment of osteoporosis and other skeletal disorders and bone imaging when linked to a gamma-emitting radioisotope.…”

mentioning

confidence: 99%

Structural Requirements for Bisphosphonate Binding on Hydroxyapatite: NMR Study of Bisphosphonate Partial Esters

Puljula

Turhanen

Vepsäläinen

et al. 2015

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

Eighteen different bisphosphonates, including four clinically used bisphosphonate acids and their phosphoesters, were studied to evaluate how the bisphosphonate structure affects binding to bone. Bisphosphonates with weak bone affinity, such as clodronate, could not bind to hydroxyapatite after the addition of one ester group. Medronate retained its ability to bind after the addition of one ester group, and hydroxy-bisphosphonates could bind even after the addition of two ester groups. Thus, several bisphosphonate esters are clearly bone binding compounds. The following conclusions about bisphosphonate binding emerge: (1) a hydroxyl group in the geminal carbon takes part in the binding process and increases the bisphosphonate's ability to bind to bone; (2) the bisphosphonate's ability to bind decreases when the amount of ester groups increases; and (3) the location of the ester groups affects the bisphosphonate's binding ability.

show abstract

Pharmacology of bisphosphonates

Cited by 189 publications

References 58 publications

Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial

Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial

Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities

Structural Requirements for Bisphosphonate Binding on Hydroxyapatite: NMR Study of Bisphosphonate Partial Esters

Contact Info

Product

Resources

About